Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients
Source: Streetwise Reports  (4/28/21)
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. More >

Company Receives Its Largest Order for Antibiotic-Free Animal Feed Product
Source: Streetwise Reports  (4/28/21)
Avivagen Inc. reported it received a 4.4 metric tonne purchase order for OxC-beta Livestock from UNAHCO representing its largest single order to date. More >

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%
Source: Streetwise Reports  (4/28/21)
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. More >

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial
Source: Streetwise Reports  (4/27/21)
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. More >

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors
Source: Streetwise Reports  (4/23/21)
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. More >

Healthcare Services Group Shares Rise 13% on Q1 Earnings and Quarterly Dividend Increase
Source: Streetwise Reports  (4/21/21)
Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income. More >

Is the Trend Turning for This Psychedelic Stock?
Source: Clive Maund for Streetwise Reports  (4/19/21)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. More >

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site
Source: Streetwise Reports  (4/16/21)
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. More >

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever
Source: Streetwise Reports  (4/16/21)
A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health
management companies." More >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3
Source: Streetwise Reports  (4/15/21)
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. More >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio
Source: Streetwise Reports  (4/14/21)
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. More >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial
Source: Streetwise Reports  (4/13/21)
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. More >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial
Source: Streetwise Reports  (4/9/21)
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. More >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'
Source: Streetwise Reports  (4/7/21)
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." More >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue
Source: Streetwise Reports  (4/7/21)
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. More >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine
Source: Streetwise Reports  (4/7/21)
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. More >

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray
Source: Streetwise Reports  (4/5/21)
Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray. More >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD
Source: Streetwise Reports  (4/1/21)
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. More >

Coverage Initiated on Health & Wellness Firm About to Launch Retail Sales, Sees 'Substantial Upside Potential'
Source: Streetwise Reports  (3/30/21)
Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market." More >

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
Source: Streetwise Reports  (3/30/21)
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. More >

Shockwave Medical Reports 100% Increase in Preliminary Q1 Revenue
Source: Streetwise Reports  (3/30/21)
Shockwave Medical Inc. shares gained 19% after the company announced that sales of its recently launched C2 Coronary IVL System are growing steadily and are driving revenue growth. More >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates
Source: Streetwise Reports  (3/29/21)
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumabâ„¢ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. More >

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
Source: Streetwise Reports  (3/25/21)
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. More >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April
Source: Streetwise Reports  (3/24/21)
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. More >

Rritual Superfoods Hits the Superhighway to Nationwide Distribution and Impressive Share Gains
Source: Knox Henderson for Streetwise Reports  (3/24/21)
Knox Henderson delves into the value proposition behind Rritual Superfoods, which has just started trading this month. More >